A Randomized Trial of Prenatal n-3 Fatty Acid Supplementation and Preterm Delivery
- PMID: 31509674
- DOI: 10.1056/NEJMoa1816832
A Randomized Trial of Prenatal n-3 Fatty Acid Supplementation and Preterm Delivery
Abstract
Background: Previous studies have suggested that maternal supplementation with n-3 long-chain polyunsaturated fatty acids may reduce the incidence of preterm delivery but may also prolong gestation beyond term; however, more data are needed regarding the role of n-3 long-chain polyunsaturated fatty acids in pregnancy.
Methods: We performed a multicenter, double-blind, randomized trial in which women who were pregnant with single or multiple fetuses were assigned to receive either fish-oil capsules that contained 900 mg of n-3 long-chain polyunsaturated fatty acids (n-3 group) or vegetable-oil capsules that contained trace n-3 long-chain polyunsaturated fatty acids (control group) daily, beginning before 20 weeks of gestation and continuing to 34 weeks of gestation or delivery, whichever occurred first. The primary outcome was early preterm delivery, defined as delivery before 34 completed weeks of gestation. Other pregnancy and neonatal outcomes were also assessed.
Results: A total of 5544 pregnancies in 5517 women were randomly assigned at six centers in Australia; 5486 pregnancies were included in the primary analysis. Early preterm delivery occurred in the case of 61 of 2734 pregnancies (2.2%) in the n-3 group and 55 of 2752 pregnancies (2.0%) in the control group; the between-group difference was not significant (adjusted relative risk, 1.13; 95% confidence interval [CI], 0.79 to 1.63; P = 0.50). There were no significant differences between the groups in the incidence of interventions in post-term (>41 weeks of gestation) deliveries, in adverse events, or in other pregnancy or neonatal outcomes, except that a higher percentage of infants born to women in the n-3 group than in the control group were very large for gestational age at birth (adjusted relative risk, 1.30; 95% CI, 1.02 to 1.65). Percentages of serious adverse events did not differ between the groups. Minor gastrointestinal disturbances were more commonly reported in the n-3 group than in the control group.
Conclusions: Supplementation with n-3 long-chain polyunsaturated fatty acids from early pregnancy (<20 weeks of gestation) until 34 weeks of gestation did not result in a lower incidence of early preterm delivery or a higher incidence of interventions in post-term deliveries than control. (Funded by the Australian National Health and Medical Research Council and the Thyne Reid Foundation; ORIP Australian New Zealand Clinical Trials Registry number, ACTRN12613001142729.).
Copyright © 2019 Massachusetts Medical Society.
Comment in
-
n-3 and preterm birth: what can we learn from the heterogeneity?Public Health Nutr. 2020 Sep;23(13):2453-2454. doi: 10.1017/S1368980019004713. Epub 2020 Apr 27. Public Health Nutr. 2020. PMID: 32338238 Free PMC article. No abstract available.
Similar articles
-
Study protocol for a randomised controlled trial evaluating the effect of prenatal omega-3 LCPUFA supplementation to reduce the incidence of preterm birth: the ORIP trial.BMJ Open. 2017 Sep 24;7(9):e018360. doi: 10.1136/bmjopen-2017-018360. BMJ Open. 2017. PMID: 28947468 Free PMC article. Clinical Trial.
-
Predictors of compliance with higher dose omega-3 fatty acid supplementation during pregnancy and implications for the risk of prematurity: exploratory analysis of the ORIP randomised trial.BMJ Open. 2023 Sep 22;13(9):e076507. doi: 10.1136/bmjopen-2023-076507. BMJ Open. 2023. PMID: 37739459 Free PMC article. Clinical Trial.
-
The effect of omega-3 supplementation on pregnancy outcomes by smoking status.Am J Obstet Gynecol. 2017 Oct;217(4):476.e1-476.e6. doi: 10.1016/j.ajog.2017.05.033. Epub 2017 May 23. Am J Obstet Gynecol. 2017. PMID: 28549983 Free PMC article. Clinical Trial.
-
Docosahexaenoic Acid and Preterm Birth.Ann Nutr Metab. 2016;69 Suppl 1:29-34. doi: 10.1159/000448263. Epub 2016 Nov 15. Ann Nutr Metab. 2016. PMID: 27842314 Review.
-
Impact of n-3 polyunsaturated fatty acid intake in pregnancy on maternal health and birth outcomes: systematic review and meta-analysis from randomized controlled trails.Arch Gynecol Obstet. 2023 Jan;307(1):249-262. doi: 10.1007/s00404-022-06533-0. Epub 2022 Mar 28. Arch Gynecol Obstet. 2023. PMID: 35348829
Cited by
-
Myo-inositol: a potential prophylaxis against premature onset of labour and preterm birth.Nutr Res Rev. 2023 Jun;36(1):60-68. doi: 10.1017/S0954422421000299. Epub 2021 Sep 16. Nutr Res Rev. 2023. PMID: 34526164 Free PMC article. Review.
-
Early and late preterm birth rates in participants adherent to randomly assigned high dose docosahexaenoic acid (DHA) supplementation in pregnancy.Clin Nutr. 2023 Feb;42(2):235-243. doi: 10.1016/j.clnu.2023.01.009. Epub 2023 Jan 11. Clin Nutr. 2023. PMID: 36680919 Free PMC article. Clinical Trial.
-
Independence estimators for re-randomisation trials in multi-episode settings: a simulation study.BMC Med Res Methodol. 2021 Oct 30;21(1):235. doi: 10.1186/s12874-021-01433-4. BMC Med Res Methodol. 2021. PMID: 34717559 Free PMC article.
-
Supplementation of Omega 3 during Pregnancy and the Risk of Preterm Birth: A Systematic Review and Meta-Analysis.Nutrients. 2021 May 18;13(5):1704. doi: 10.3390/nu13051704. Nutrients. 2021. PMID: 34069867 Free PMC article.
-
Effect of Omega-3 Supplementation in Pregnant Women with Obesity on Newborn Body Composition, Growth and Length of Gestation: A Randomized Controlled Pilot Study.Nutrients. 2021 Feb 9;13(2):578. doi: 10.3390/nu13020578. Nutrients. 2021. PMID: 33572368 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical